Free Trial

Phathom Pharmaceuticals Q3 2024 Earnings Report

Phathom Pharmaceuticals logo
$5.17 -0.32 (-5.83%)
As of 12:20 PM Eastern

Phathom Pharmaceuticals EPS Results

Actual EPS
-$1.32
Consensus EPS
-$1.57
Beat/Miss
Beat by +$0.25
One Year Ago EPS
-$0.76

Phathom Pharmaceuticals Revenue Results

Actual Revenue
$16.35 million
Expected Revenue
$12.54 million
Beat/Miss
Beat by +$3.81 million
YoY Revenue Growth
N/A

Phathom Pharmaceuticals Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Remove Ads

Phathom Pharmaceuticals Earnings Headlines

Needham Remains a Buy on Phathom Pharmaceuticals (PHAT)
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Phathom Pharmaceuticals appoints Basta as President, CEO
See More Phathom Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Phathom Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phathom Pharmaceuticals and other key companies, straight to your email.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals (NASDAQ:PHAT), biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

View Phathom Pharmaceuticals Profile

More Earnings Resources from MarketBeat